RBL LLC has landed an investment from Houston-based Modi Ventures and named its founder, Sahir Ali (far left), to its board. Photo courtesy Rice University Biotech Launch Pad via LinkedIn

RBL LLC, which supports commercialization for ventures formed at the Rice University Biotech Launch Pad, has secured an investment from Houston-based Modi Ventures.

Additionally, RBL announced that it has named Sahir Ali, founder and general partner of Modi Ventures, to its board of directors.

Modi Ventures invests in biotech companies that are working to advance diagnostics, engineered therapeutics and AI-driven drug discovery. The firm has $134 million under management after closing an oversubscribed round this summer.

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. William McKeon, president and CEO of the TMC, previously called the launch of RBL a “critical step forward” for Houston’s life sciences ecosystem.

“RBL is dedicated to building companies focused on pioneering and intelligent bioelectronic therapeutics,” Ali said in a LinkedIn post. “This partnership strengthens the Houston biotech ecosystem and accelerates the transition of groundbreaking lab discoveries into impactful therapies.”

Ali will join board members like managing partner Paul Wotton, Rice bioengineering professor Omid Veiseh, scientist and partner at KdT Ventures Rima Chakrabarti, Rice alum John Jaggers, CEO of Arbor Biotechnologies Devyn Smith, and veteran executive in the life sciences sector James Watson.

Ali has led transformative work and built companies across AI, cloud computing and precision medicine. Ali also serves on the board of directors of the Drug Information Association, which helps to collaborate in drug, device and diagnostics developments.

“This investment by Modi Ventures will be instrumental to RBL’s growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups,” Wotton said in the announcement. "Sahir’s addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission.”

Sentinel BioTherapeutics is developing cytokine interleukin-2 (IL-2) capsules to fight many solid tumors. Photo via Getty Images.

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

Omid Veiseh from Rice University and Edward Ratner from the University of Houston have been named 2024 National Academy of Inventors fellows for their innovative contributions. Courtesy photos

2 Houston professors named as fellows for prestigious group of inventors

top innovators

The highest professional distinction awarded to academic inventors, the National Academy of Inventors, have elected two fellows from Rice University and the University of Houston for its 2024 class.

Edward Ratner, computer information systems lecturer in the Department of Information Science Technology at the University of Houston’s Cullen College of Engineering, and Omid Veiseh, bioengineer at Rice University and director of the Biotech Launch Pad, were two of the 170 honorees representing 39 states and 12 countries.

The 2024 class will be honored and presented their medals on June 26 in Atlanta, Georgia by a senior official of the U.S. Patent and Trademark Office.

Ratner’s research includes artificial intelligence, machine learning, image analysis, video compression and video streaming, and has led to 40 patents currently. His inventions on adaptive video streaming assists the technology used today for streaming video over the internet. Ratner becomes the 40th UH faculty who is either a fellow or senior member of the NAI.

“Ed Ratner’s recognition as a Fellow of the NAI is a testament to his exceptional creativity, dedication and impact in advancing innovation,” Ramanan Krishnamoorti, vice president of energy and innovation at UH, says in a news release. “Here at the University of Houston, we take great pride in fostering a culture where visionary thinkers like Ed can thrive. This honor reflects not only his remarkable achievements but also the University’s commitment to shaping the future through groundbreaking research and invention.”

Veiseh is a current professor of bioengineering, a Cancer Prevention and Research Institute of Texas Scholar and faculty director of the Rice Biotech Launch Pad, which is a Houston-based accelerator that focuses on “expediting the translation of the university’s health and medical technology discoveries into cures,” according to a news release from Rice.

His research focuses on developing innovative treatments that involve combining synthetic biology, molecular engineering and advanced materials science. He also helped lead a $45 million project funded by the Advanced Research Projects Agency for Health (ARPA-H) to create implantable cancer monitoring and treatment devices.

“It is our mission to make sure that scientific and technological advancements are translated from laboratory discoveries into life-saving cures and products that have a real and enduring impact on patients’ lives,” said Veiseh in a news release. “I am honored to be recognized by this distinguished award and would like to thank my collaborators at Rice and elsewhere for working toward this shared goal of improving lives through better, more effective treatments.”

In

2023, UH’s Vincent Donnelly, Moores professor of Chemical and Biomolecular Engineering, and Christine Ehlig-Economides, Hugh Roy and Lillie Cranz Cullen Distinguished university chair of Petroleum Engineering, all received the Fellows honor. Other 2024 Texas-based fellows include Malcom Brenner from Baylor College of Medicine, Maria Croyle from The University of Texas at Austin, Jaime Grunlan from Texas A&M University, and more.
Established to rapidly build companies based on Rice University's portfolio of over 100 patents, RBL LLC is a new biotech venture creation studio based in Texas Medical Center Helix Park. Photo courtesy of Rice

Rice University opens biotech venture studio in TMC

rapidly scaling

In its mission to amplify and advance biotech innovation, Rice University has announced its latest initiative — a new lab focused on bringing life-saving medical technologies to commercialization.

Established to rapidly build companies based on Rice University's portfolio of over 100 patents, RBL LLC is a new biotech venture creation studio based in Texas Medical Center Helix Park. RBL comes on the heels of establishing the Rice Biotech Launch Pad, a biotech innovation accelerator that opened last year.

Paul Wotton, executive director of the Rice Biotech Launch Pad, co-founded RBL with his colleagues Omid Veiseh, Rice professor of bioengineering and faculty director of the Rice Biotech Launch Pad; Jacob Robinson, Rice professor of electrical and computer engineering; and Dr. Rima Chakrabarti, a physician scientist and venture capital investor with KdT Ventures.

“This is a pivotal moment for Houston and beyond,” Wotton, who serves as RBL’s managing partner, says in a news release from Rice. “Houston has rapidly emerged as a global life sciences powerhouse, blending cutting-edge research with early clinical applications at Rice and the city’s world-renowned hospital systems.

"Investors from across the nation are recognizing Houston’s potential, and with RBL, we’re building on that momentum," he continues. "We’ll not only amplify the work of the Rice Biotech Launch Pad but expand our reach across Texas, creating opportunities for biotech ventures statewide and driving growth for the biotech industry as a whole.”

Strategically located in TMC, RBL will collaborate with medical leaders, investors, corporations, and other players both in the same building and on the greater TMC campus.

“Leveraging Rice University’s Biotech Launch Pad breakthroughs and pairing it with the world-class translational infrastructure of TMC Helix Park well positions RBL to drive unprecedented advances in patient care,” William McKeon, president and CEO of the TMC, says in the release. “This partnership between academia, industry and health care is exactly what’s needed to transform medical discoveries into real-world solutions that improve lives globally.”

RBL is Rice's latest effort to bridge the gap between academia and biotech innovation, an effort led by Paul Cherukuri, Rice’s chief innovation officer, who reportedly spearheaded development of the new initiative.

“RBL is a game-changer for Rice, Houston and the global biotech community,” Cherukuri adds. “This venture not only accelerates the commercialization of our innovations but also sets a blueprint for other universities looking to maximize the real-world impact of their discoveries. By combining scientific expertise with entrepreneurial support from Day Zero together with strategic clinical partnerships in the TMC, we’re creating a model for driving large-scale biotech innovation that universities everywhere should aspire to replicate.”

Since the Rice Biotech Launch Pad was established, Motif Neurotech closed its series A round with an oversubscribed $18.75 million, the hub secured a $34.9 million grant, and a “living pharmacy” founded at the Launch Pad received industry validation.

“RBL provides a powerful platform to translate high-impact scientific discoveries into therapies that will dramatically improve patient outcomes,” Veiseh says. “Our goal is to rapidly bring Rice’s pioneering research into the clinic, delivering life-saving solutions to patients around the world.”

Rice’s Biotech Launch Pad will lead the effort to commercialize the device. Photo courtesy Rice University

Rice researchers secure $35M federal grant to advance medical device technology

big money

Rice University has secured part of a nearly $35 million federal grant aimed at commercializing a bioelectric implant for treatment of type 2 diabetes and obesity.

The federal Advanced Research Projects Agency for Health awarded the $34.9 million grant to Rice and several other universities.

Rice’s Biotech Launch Pad will lead the effort to commercialize the self-contained, implantable Rx On-site Generation Using Electronics (ROGUE) device. ROGUE houses cells that are engineered to produce type 2 diabetes and obesity therapies in response to patients’ needs.

Carnegie Mellon University leads the team of researchers handling development and testing of ROGUE, which acts as a “living pharmacy” designed to make biologic drugs available on demand in a patient’s body.

The ROGUE initiative aims to keep the cost of this treatment significantly below the cost of other biologics-based treatments.

“ROGUE’s innovative design combines efficient biological manufacturing, long-term durability, and patient-friendly features that have the potential to transform the landscape of biologics delivery,” Omid Veiseh, professor of bioengineering and faculty director of the Rice Biotech Launch Pad, says in a news release.

Paul Wotton, an in-house entrepreneur at the university and executive director of the Rice accelerator, is helping guide ROGUE toward becoming an independent company.

“With the Biotech Launch Pad, our goal is venture creation in parallel to the groundbreaking research at Rice and its collaborating institutions,” Wotton says.

Omid Veiseh is professor of bioengineering and faculty director of the Rice Biotech Launch Pad. Photo courtesy Rice University

The two new awardees are LymphGuide and HEXASpec, which were selected from 26 applications. Each company received an $100,000 grant. Photo courtesy of The Ion

2 lab-stage Houston startups receive fresh funding from Rice University grant program

cashing in on innovation

Rice University has doled out another batch of grants from its program supporting lab-based innovations.

The One Small Step Grant, which was announced a year ago and gave out its first grants in February, was established to fund Rice-founded, lab-stage projects on their path to commercialization

“The One Small Step Grant invites applications from students and faculty who are tackling some of the world’s most pressing challenges and preparing to bring their innovative technologies to market,” Nafisa Istami, innovation manager at Rice, says in a news release. “We received highly competitive applications from across campus, truly showcasing the growing momentum of technology innovation happening at Rice.”

The two new awardees are LymphGuide and HEXASpec, which were selected from 26 applications. Each company received an $100,000 grant.

LymphGuide was developed by Martha Fowler in Rice professor Omid Veiseh’s lab. The hydrogel platform is a customizable alginate that's combined with an engineered cell therapy to aid in lymphatic cell regrowth, initially targeting the treatment and prevention of lymphedema.

"We are profoundly grateful to the One Small Step Grant for supporting our vision to treat lymphedema,” says Martha Fowler, cofounder of LymphGuide. “This funding will propel our biotechnology into pre-clinical evaluation to make a meaningful impact in scientific research and for people suffering from lymphatic disease.” Fowler is also an active contributor in the Rice entrepreneurship ecosystem and an Liu Idea Lab of Innovation and Entrepreneurship Innovation Fellows Cohort 2 member.

Led by by Tianshu Zhai in Rice professor Jun Lou’s lab, HEXASpec develops inorganic fillers and molding compounds for next-generation chip packaging. Zhai is also one of the Liu Idea Lab of Innovation and Entrepreneurship Innovation Fellows.

“We are thrilled to receive the One Small Step Grant from Rice Innovation,” says Tianshu Zhai, cofounder of HEXASpec. “This support is crucial for advancing HEXASpec and signifies the strong backing of the Rice entrepreneurship community. We’re grateful for the opportunity to develop our technology with such robust support.”

The next round of grant opportunities will open next month with an online application process.

“The One Small Step Grant program is a demonstration of Rice’s commitment to supporting the commercialization of Rice technologies,” says Adrian Trömel, associate vice president of Innovation Strategy and Investments. “Each cycle further highlights the impactful work of Rice students and faculty to solve global problems across industries.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Oxy's $1.3B Texas carbon capture facility on track to​ launch this year

gearing up

Houston-based Occidental Petroleum is gearing up to start removing CO2 from the atmosphere at its $1.3 billion direct air capture (DAC) project in the Midland-Odessa area.

Vicki Hollub, president and CEO of Occidental, said during the company’s recent second-quarter earnings call that the Stratos project — being developed by carbon capture and sequestration subsidiary 1PointFive — is on track to begin capturing CO2 later this year.

“We are immensely proud of the achievements to date and the exceptional record of safety performance as we advance towards commercial startup,” Hollub said of Stratos.

Carbon dioxide captured by Stratos will be stored underground or be used for enhanced oil recovery.

Oxy says Stratos is the world’s largest DAC facility. It’s designed to pull 500,000 metric tons of carbon dioxide from the air and either store it underground or use it for enhanced oil recovery. Enhanced oil recovery extracts oil from unproductive reservoirs.

Most of the carbon credits that’ll be generated by Stratos through 2030 have already been sold to organizations such as Airbus, AT&T, All Nippon Airways, Amazon, the Houston Astros, the Houston Texans, JPMorgan, Microsoft, Palo Alto Networks and TD Bank.

The infrastructure business of investment manager BlackRock has pumped $550 million into Stratos through a joint venture with 1PointFive.

As it gears up to kick off operations at Stratos, Occidental is also in talks with XRG, the energy investment arm of the United Arab Emirates-owned Abu Dhabi National Oil Co., to form a joint venture for the development of a DAC facility in South Texas. Occidental has been awarded up to $650 million from the U.S. Department of Energy to build the South Texas DAC hub.

The South Texas project, to be located on the storied King Ranch, will be close to industrial facilities and energy infrastructure along the Gulf Coast. Initially, the roughly 165-square-mile site is expected to capture 500,000 metric tons of carbon dioxide per year, with the potential to store up to 3 billion metric tons of CO2 per year.

“We believe that carbon capture and DAC, in particular, will be instrumental in shaping the future energy landscape,” Hollub said.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New app by Sports Illustrated grants access to 700 sports courts in Houston

Goal!

A new sports center booking app CatchCorner, powered by Sports Illustrated, enables sports enthusiasts in Houston to seamlessly secure a spot for a quick game without membership fees.

It soft-launched in Houston this spring and, according to co-founder and chief operating officer Maya Azouri, has been a huge success.

"The Houston expansion has been jaw-dropping," she said. "Up until now, CatchCorner’s launch in New York City had been our most successful market, but Houston has launched on par with it."

Within a 30-day period this summer, over 30,000 users join the app, Azouri noted, adding that the app would include 700 unique recreational spaces users can choose from in the city.

"There’s a real sports culture here, with athletes of all levels from casual weekend players to competitive amateurs and even pros. The diversity of the sports community, combined with the number of high-quality facilities across the city, makes it a perfect fit for CatchCorner," she said.

CatchCorner in Houston offers bookings for basketball, volleyball, soccer, pickleball, padel, baseball, badminton, and tennis, with plans to include golf simulators and ice rink sports soon. The Zone Sports, Toros HTX, PAC Gym, and Houston Pickleball Center are among the most popular venues.

Using the app is a snap. Once you pick your sport, venues with available slots are listed including distance from you with the booking schedules in the results so there are no surprises. The slots can go fast, so occasional error messages pop up when trying to book, but it's otherwise a three-click process. CatchCorner also helpfully includes a picture of the facilities while booking.

CatchCorner announced Google integration in June that lets users book through the app directly from searches when they look up specific venues. This is slightly less intuitive to use than the app, but it does ultimately work in both mobile and desktops versions. Either way, it greatly streamlines the booking process for people who just want to schedule a quick pickup game somewhere.

"It’s especially useful for casual players or people who want to organize something on short notice," said Azouri. "Whether it’s a weekend basketball run, a weekday futsal match, or a spontaneous pickleball game with friends, CatchCorner makes it easy to coordinate without the usual logistical headaches.

"Some feedback here has been that we’re like 'Expedia for sports.' It’s because booking a flight online is that easy, booking your next game or workout should be just as simple."

---

This article originally appeared on CultureMap.com.

10 Houston billionaires make Forbes' list of richest Americans in 2025

The Rich List

America's wealthiest billionaires are $1.2 trillion richer in 2025, bringing their collective worth to a staggering $6.6 trillion. And Houston's own Richard Kinder has become the richest billionaire in the city, according to the new Forbes 400.

The Kinder Morgan chairman is the 11th richest Texas resident and ranks as the 108th richest American. Kinder also dethroned Tilman Fertitta to claim the title as the wealthiest Houstonian.

The annual Forbes 400 list is a definitive ranking of the wealthiest Americans, using interviews, financial data, and documentation provided by billionaires and their companies.

Kinder's wealth

The publication estimates Kinder's net worth at $10.6 billion, up from $8.1 billion last year. He also appears among Forbes' separate list of the richest billionaires in the world.

"It’s been a year unlike any we’ve seen in the four decades we’ve tracked America’s billionaire class,” said Forbes senior editor Chase Peterson-Withorn in a press release. "The super-rich at the very top are richer than ever — and between the White House and the booming stock market, they’re as powerful as they’ve ever been."

Kinder, 80, co-founded oil and gas pipeline firm Kinder Morgan in 1997, which is now known as one of the largest American energy infrastructure companies. He stepped down as CEO in 2015, though he still chairs the board of directors.

Kinder and his wife, Nancy, also founded Houston-based nonprofit the Kinder Foundation in 1997. The organization provides "major gifts to public causes with the intention of helping people realize healthy and rewarding lives," according to its website.

In May 2025, the Kinders pledged $150 million to Texas Children's Hospital and MD Anderson to create the Kinder Children's Cancer Center.

"Our philanthropic efforts center on supporting transformational projects in Houston, and this initiative exemplifies that mission in every way," said Kinder in a press release. "We were deeply impressed by the extraordinary leadership and unwavering commitment of both UT MD Anderson and Texas Children’s to pursue a bold, collaborative model of care. It is a rare and powerful moment when two leading organizations come together to create something entirely new – something capable of reshaping the future of pediatric cancer care."

The richest Houstonians

In all, 43 Texas billionaires made it on the 2025 Forbes 400 list, and 10 are based in the Houston metro.

Hospitality honcho Fertitta, 68, is the second-richest billionaire in Houston, and his net worth has jumped from $10.1 billion last year to $11 billion in 2025. He owns the Golden Nugget Casinos, the Houston Rockets, Texas-based restaurant and entertainment company Landry's, and also serves as the U.S. Ambassador to Italy.

"Serving as President Trump's ambassador to Italy 'is a real job,' says Fertitta, who personally oversaw the renovation of Villa Taverna, the ambassador's residence in Rome," Forbes wrote in his profile.

Fertitta most recently put his ritzy 250-foot-long superyacht on the market for about $192 million, with Forbes saying he "has a bigger one on order."

Here's how the rest of Houston's billionaires fared on this year's list:

  • Oil tycoon Jeffery Hildebrand ties for No. 123 nationally with an estimated net worth of $10 billion. Last year: $7.6 billion.
  • Toyota mega-dealer Dan Friedkin ranks 128th nationally with an estimated net worth of $9.7 billion. Last year: $7.6 billion.
  • Houston pipeline heir Randa Duncan Williams ranks 130th with an estimated net worth of $9.5 billion. Fellow pipeline heirs Dannine Avara and Milane Frantz tie for 135th nationally. Each has an estimated net worth of $9.4 billion. Scott Duncan ranks No. 141 with a $9.2 billion estimated net worth.
  • Houston Texans owner Janice McNair ranks 201st nationally with an estimated net worth of $7.3 billion. Last year: $6.2 billion.
  • Energy exploration chief exec George Bishop of The Woodlands ranks No. 325 with an estimated net worth of $4.7 billion. Last year: $5 billion.

Richest billionaires elsewhere in Texas

The richest person in America in 2025 is none other than Austin-based Elon Musk. Musk, 54, saw his net worth skyrocket to $428 billion this year, or $184 billion more than his 2024 net worth. He claimed the No. 1 spot for the fourth time.

Walmart heiress Alice Walton of Fort Worth was dubbed the wealthiest woman in America for 2025. Walton, 75, simultaneously holds the title as the richest woman in the world. Forbes estimates Walton's net worth at $106 billion (up from $89.2 billion last year) and proclaims her as the first female centibillionaire (a person with a 12-digit fortune) in America. Now that's wealth.

"Tariffs. Inflation. Slowing employment. None of it has hit the fortunes of America’s billionaires," Forbes said. "A decade ago, when it took $1.7 billion to make The Forbes 400, a net worth of $3.8 billion was comfortably within the top half of the ranking — now that lofty sum is the minimum required."

---

This article originally appeared on CultureMap.com.